Results 51 to 60 of about 51,615 (305)

SRSF2 Is Essential For Hematopoiesis and Its Mutations Dysregulate Alternative RNA Splicing In MDS [PDF]

, 2013
Myelodysplastic syndromes (MDS) are a group of neoplasms that are ineffective in generating multiple lineages of myeloid cells and have various risks to progress to acute myeloid leukemia.
Chen, Liang, Dekelver, Russell, Fu, Xiang-Dong, Heuser, Michael, Komeno, Yukiko, Lin, Leo, Monterroza, Dora D, Qiu, Jinsong, Thol, Felicitas, Xu, YiJun, Zhang, Dong-Er   +10 more
core  

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish Registry [PDF]

, 2015
The benefit of azacitidine treatment in survival of high risk myelodysplastic syndromes (MDS) patients compared to conventional care treatment (CCT) has not been established outside clinical trials.
Amigo, M. L., Ardanaz, María Teresa, Bernal del Castillo, Teresa, Luño Fernández, Elisa, Martínez Camblor, Pablo, Nomdedeu, Benet, Paz, Raquel de, Pedro, Carme, Sánchez García, Joaquín, Xicoy, Blanca   +9 more
core   +1 more source

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

Haematologica, 2017
Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9, serves as a Toll-like receptor ligand regulating tumor necrosis factor-α and interleukin-1β ...
Thomas Cluzeau, Kathy L. McGraw, Brittany Irvine, Erico Masala, Lionel Ades, Ashley A. Basiorka, Jaroslaw Maciejewski, Patrick Auberger, Sheng Wei, Pierre Fenaux, Valeria Santini, Alan List   +11 more
doaj   +1 more source

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. [PDF]

, 2019
BackgroundNovel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML ...
Bejar, Rafael, Bell, Jill A, Cano, Stefan, Faller, Douglas V, Fram, Robert J, Galaznik, Aaron, Marquis, Patrick, Pompilus, Farrah, Scipione, Fatima, Strzok, Sara   +9 more
core  

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes [PDF]

, 2013
The reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is uncertain and its assessment was the major aim of this study.
Arenillas, Leonor, Florensa Brichs, Lourdes, Luño Fernández, Elisa, Ruiz, Juan C., Sanz, Guillermo, Senent, Leonor, Spanish MDS Cooperat Grp GESMD   +6 more
core   +1 more source

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes (LR‐MDS) in the COMMANDS Study

American Journal of Hematology, EarlyView.
ABSTRACT The COMMANDS trial established luspatercept as a first‐line treatment for anemia in transfusion‐dependent lower‐risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS ...
Rami S. Komrokji, Sheida Hayati, Manuel Ugidos, Guillermo Garcia‐Manero, Matteo Giovanni Della Porta, Amer M. Zeidan, Valeria Santini, Uwe Platzbecker, Anita K. Gandhi, Rajasekhar N. V. S. Suragani   +9 more
wiley   +1 more source

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

Haematologica, 2012
Background There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether erythropoiesis stimulating agents are associated with an increased risk of thrombosis in ...
Sheila Weiss Smith, Masayo Sato, Steven D. Gore, Maria R. Baer, Xuehua Ke, Diane McNally, Amy Davidoff   +6 more
doaj   +1 more source

Myelodysplasia in a psoriasis patient receiving etanercept : Cause or coincidence? [PDF]

, 2018
Peer reviewedFinal Accepted ...
Ayoub, Othman Hadi, Dawoud, Dalia M, Dawoud, Noha Mohammed, Essa, Enas Said   +3 more
core   +3 more sources

Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

American Journal of Hematology, EarlyView.
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang, Ruonan Li, Qian Liang, Weiwang Li, Hong Pan, Zhen Gao, Liwei Fang, Jingyu Zhao, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Meili Ge, Yizhou Zheng, Jun Li, Hong Zhang, Jun Shi   +18 more
wiley   +1 more source

Clinical and genetic predictors of prognosis in myelodysplastic syndromes

Haematologica, 2014
Myelodysplastic syndromes are a collection of clonal hematopoietic disorders with a wide range of clinical manifestations and eventual outcomes. Accurate prediction of a patient’s prognosis is useful to define the risk posed by the disease and which ...
Rafael Bejar
doaj   +1 more source